44 Wealth Management LLC Sells 185 Shares of Novo Nordisk A/S (NYSE:NVO)

44 Wealth Management LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,759 shares of the company’s stock after selling 185 shares during the period. 44 Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $237,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in NVO. Hennion & Walsh Asset Management Inc. increased its stake in shares of Novo Nordisk A/S by 105.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 18,041 shares of the company’s stock worth $2,148,000 after purchasing an additional 9,272 shares during the period. Tectonic Advisors LLC increased its stake in shares of Novo Nordisk A/S by 6.6% during the third quarter. Tectonic Advisors LLC now owns 5,512 shares of the company’s stock worth $656,000 after purchasing an additional 340 shares during the period. Capital Management Associates Inc increased its stake in shares of Novo Nordisk A/S by 3.7% during the third quarter. Capital Management Associates Inc now owns 3,299 shares of the company’s stock worth $393,000 after purchasing an additional 119 shares during the period. Country Club Bank increased its stake in shares of Novo Nordisk A/S by 11.3% during the third quarter. Country Club Bank now owns 1,837 shares of the company’s stock worth $222,000 after purchasing an additional 187 shares during the period. Finally, Convergence Financial LLC increased its stake in shares of Novo Nordisk A/S by 41.0% during the third quarter. Convergence Financial LLC now owns 11,151 shares of the company’s stock worth $1,328,000 after purchasing an additional 3,243 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 5.2 %

Shares of NVO stock opened at $88.07 on Friday. The stock’s fifty day moving average price is $86.01 and its two-hundred day moving average price is $108.07. The company has a market cap of $395.19 billion, a PE ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

Analysts Set New Price Targets

NVO has been the topic of a number of recent research reports. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.